We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, June 28th:
Xcerra Corporation : This test and handling capital equipment provider, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings advancing 4% over the last 60 days.
Dillard's, Inc. (DDS - Free Report) : This retail department stores operator, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.3% over the last 60 days.
International Paper Company (IP - Free Report) : This paper and packaging company, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings rising 2.8% over the last 60 days.
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Top Ranked Growth Stocks to Buy for June 28th
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, June 28th:
Xcerra Corporation : This test and handling capital equipment provider, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings advancing 4% over the last 60 days.
Xcerra Corporation Price and Consensus
Xcerra Corporation price-consensus-chart | Xcerra Corporation Quote
Xcerra has a PEG ratio of 1.11, compared with 1.89 for the industry. The company possesses a Growth Score of A.
Xcerra Corporation PEG Ratio (TTM)
Xcerra Corporation peg-ratio-ttm | Xcerra Corporation Quote
Dillard's, Inc. (DDS - Free Report) : This retail department stores operator, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.3% over the last 60 days.
Dillard's, Inc. Price and Consensus
Dillard's, Inc. price-consensus-chart | Dillard's, Inc. Quote
Dillard's has a PEG ratio of 1.53, compared with 9.26 for the industry. The company possesses a Growth Score of A.
Dillard's, Inc. PEG Ratio (TTM)
Dillard's, Inc. peg-ratio-ttm | Dillard's, Inc. Quote
International Paper Company (IP - Free Report) : This paper and packaging company, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings rising 2.8% over the last 60 days.
International Paper Company Price and Consensus
International Paper Company price-consensus-chart | International Paper Company Quote
International Paper has a PEG ratio of 1.09, compared with 1.51 for the industry. The company possesses a Growth Score of A.
International Paper Company PEG Ratio (TTM)
International Paper Company peg-ratio-ttm | International Paper Company Quote
See the full list of top ranked stocks here
Learn more about the Growth score and how it is calculated here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>